rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    FEMY
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Femasys earnings missed by $0.06, revenue fell short of estimates
      Nov 16Investing.comFEMY
      Femasys Announces Financial Results for Quarter Ended September 30, 2026 and Provides Corporate Update

      $30 million private placement supports commercial team build-out to drive U.S. sales growth; Q3 U.S. sales increased slightly despite significant funding constraints prior to mid-August financingATLANTA, Nov. 13, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the standard of care, expand access, and reduce costs for women worldwide, announces its financ

      Nov 13Yahoo FinanceFEMY
      Femasys Appoints John Moorhead to Board of Directors

      ATLANTA, Oct. 30, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the standard of care, expand access, and reduce costs for women worldwide, announced today the appointment of John Moorhead to its Board of Directors as a board designee in connection with the Company’s August 2026 private placement. Mr. Moorhead brings more than two decades of experience

      Oct 30Yahoo FinanceFEMY
      Femasys Partners with SandsRx Pharmacy to Support FemaSeed® Fertility Portfolio Launch to OB/GYNs

      First in a planned network of specialty pharmacy partnerships provides medication coordination and preferred pricing for OB/GYNs and their patientsATLANTA, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the standard of care, expand access, and reduce costs for women worldwide, announced today an agreement with SandsRx Pharmacy, marking the firs

      Oct 20Yahoo FinanceFEMY
      Femasys Doubles Enrolling Sites in FemBloc FINALE Pivotal Trial for Non-Surgical Permanent Birth Control

      -- Twelve academic and private clinical sites across the U.S. broaden patient access to the pivotal trial as Femasys advances FemBloc toward potential FDA approval --ATLANTA, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the standard of care, expand access, and reduce costs for women worldwide, announced today that it has doubled the number of

      Oct 14Yahoo FinanceFEMY
      Femasys: If The Sales Force Delivers, Then FEMY Is In Tall Cotton

      Femasys is a commercial-stage medtech company targeting OB/GYNs with in-office fertility and permanent birth control solutions. See why FEMY stock is a Buy.

      Oct 14Seeking AlphaFEMY
      Femasys to Showcase FemaSeed Fertility Treatment at ASRM 2026 as Commercialization Strategy Expands
      Oct 8Yahoo FinanceFEMY
      Femasys to Exhibit at the ASRM 2026 Scientific Congress & Expo
      Oct 8Yahoo FinanceFEMY
      Femasys Advances OB/GYN Expansion with Adoption of FemaSeed® Fertility Portfolio by Minnesota Women’s Care

      -- Leading multi-site OB/GYN health practice to implement FemVue® for fertility diagnostic evaluation and FemaSeed for first-line treatment across all four locations -- ATLANTA, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the standard of care, expand access, and reduce costs for women worldwide, announced today that Minnesota Women’s Care w

      Sep 15Yahoo FinanceFEMY
      Femasys Partners with CapexMD to Expand Patient Access to FemaSeed® Fertility Portfolio
      Sep 9Yahoo FinanceFEMY
      Femasys partners with UNC Health for fertility services
      Aug 26Investing.comFEMY
      Femasys Partners with UNC Health to Introduce Its FemaSeed® Fertility Portfolio Across Statewide OB/GYN Care Locations

      -- For the first time, OB/GYNs within the UNC Health system will be able to offer women FemVue® fertility evaluation and FemaSeed as a first-line treatment option -- ATLANTA, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the standard of care, expand access, and reduce costs for women worldwide, announced today a partnership with UNC Health to

      Aug 26Yahoo FinanceFEMY

      This is the newest page. Registered accounts read further back.